Sonoma Pharmaceuticals, Inc. (SNOA)
Sonoma Pharmaceuticals, Inc. (SNOA)
| Income Statement | 2026-03-31 | 2025-03-31 | ||
|---|---|---|---|---|
| Revenues | 19,529 | 14,288 | ||
| Cost of revenues | 12,114 | 8,823 | ||
| Gross profit | 7,415 | 5,465 | ||
| Research and development | 2,271 | 1,814 | ||
| Selling, general and administrative | 7,605 | 7,361 | ||
| Total operating expenses | 9,876 | 9,175 | ||
| Loss from operations | -2,461 | -3,710 | ||
| Other (expense) income | -958 | 803 | ||
| Loss from operations before income taxes | -3,419 | -2,907 | ||
| Income tax benefit (expense) | -244 | 550 | ||
| Net loss | -3,175 | -3,457 | ||
| Foreign currency translation adjustments | 1,133 | -1,653 | ||
| Comprehensive loss | -2,042 | -5,110 | ||
| Basic EPS | -1.89 | -2.79 | ||
| Diluted EPS | -1.89 | -2.79 | ||
| Basic Average Shares | 1,684,000 | 1,241,000 | ||
| Diluted Average Shares | 1,684,000 | 1,241,000 | ||